Global NASH Market – Analysis By Drug Type, Sales Chanel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)

Global NASH Market – Analysis By Drug Type, Sales Chanel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)

  • March 2021 •
  • 210 pages •
  • Report ID: 6044962 •
  • Format: PDF
Executive Summary
The Global NASH market valued at USD 3369.12 Million in the year 2020 is projected to grow due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. The market is expected to be driven by rise in advanced technology such as advanced clinical trials, special MRI technology, called MR-EFF (elastography fat fraction) to determine the percentage of fat and scarring present. This non-invasive diagnostic tool may eliminate the need for a liver biopsy.

Lifestyle interventions are the first-line approach to manage patients with NASH. If NASH is suspected, the patient will undergo a liver biopsy. During this procedure, a needle is used to remove a small piece of tissue from the liver, which will then be examined under a microscope. This allows the physician to determine if any scarring or inflammation of the liver tissue has occurred. Patients are usually sedated during the liver biopsy.

North America holds the major market share in 2020 with Canada’s influence in global NASH markets cannot go unnoticed which is propelling the regional industry outlook.

On the basis of Sales Channel, Retail Pharmacy is expected to hold significant share in the market over the forecast period due to certain biopharmaceutical manufacturers or companies that sell their drugs to few retail pharmacies so they will always have an advantage with these medications.

Although, the Covid-19 pandemic have taken a major toll on the market dynamics, despite which market seems to grow moderately with time but major concerns may be seen in the future such as the R&D efforts and ability to raise funds. The pandemic could also affect the operations of the FDA, EMA and other health authorities, which could delay clinical development efforts and the review and approval of product candidates, including OCA for liver fibrosis due to NASH.

Scope of the Report
• The report analyses the NASH Market by value (USD Million).

• The report analyses the NASH Market by Sales Channel – Hospital Pharmacy, Online Provider, Retail Pharmacy.

• The report analyses the NASH Market by By Drug Type – Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Others.

• The Global NASH Market has been analysed By Country - United States, Canada, Germany, France, United Kingdom, Italy, Japan, China, India, Mexico, Brazil

• The key insights of the report have been presented through the frameworks of SWOT analysis. Also, the attractiveness of the market has been presented by region, by Sales Channel, by Drug Type. Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis AG, 3M Company, Zydus Cadila, Intercept Pharmaceuticals, SHIRE PLC , Allergan plc( Tobira), Genfit SA, Astra Zeneca, Horizon Therapeutics, Gilead Sciences.

• The report presents the analysis of NASH market for the historical period of 2016-2020 and the forecast period of 2021-2026.

Key Target Audience

• Healthcare an Pharmaceutical Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities

We are very sorry, but an error occurred.
Please contact if the problem remains.